HIV/AIDS shillfactor.net

Ho	Volberding	Hirsch	Mellors	Schooley
Why this matters	*	Procrit Pushers	*	Shillfactor blog

"Chip" Schooley

From the October 2006 revisions to the DHHS adult and adolescent HIV treatment guidelines (appendix A):

Dr. Schooley serves on the HIV Advisory Boards for and receives compensation from:
Achillion Pharmaceuticals
Anormed (acquired by Genzyme 12/06)
Tanox, Inc. (acquired by Genentech 01/07)
Vertex Pharmaceuticals
ViroLogic (now Monogram Biosciences)

Dr. Schooley serves as a paid consultant for:
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Merck & Co.
Pfizer
Roche-Trimeris

Dr. Schooley owns stock in the following companies with HIV products currently licensed or in development:
Achillion Pharmaceuticals
Anormed (acquired by Genzyme in December 2006)
Tanox, Inc. (acquired by Genentech in January 2007)
Vertex Pharmaceuticals
ViroLogic (now Monogram Biosciences)

2004 conflict of interest/competing interest disclosures for Robert W. "Chip" Schooley

From the DHHS treatment guidelines (10/29/2004)

Achillion Scientific: Advisory Board, stock option

Bristol-Myers Squibb: Consultant

Gilead: Consultant, Scientific Advisory Board

GlaxoSmithKline: Consultant, research support

Merck: Consultant, research support, Scientific Advisory Board

Pfizer: Consultant

Hoffmann-La Roche: Consultant

Vertex: Scientific Advisory Board, stock

Virologic: Scientific Advisory Board, stock options

Source: see new Appendix A, "DHHS Panel on Clinical Practices for Treatment of HIV Infection Conflict of Interest Disclosure – October 2004," of the DHHS "Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents" at http://www.aidsinfo.nih.gov/guidelines/adult/AA_102904.html(accessed March 26, 2005)

From the IAS treatment guidelines (07/14/2004)

Dr Schooley is a paid consultant for:

Abbott Laboratories
Bristol-Myers Squibb
GlaxoSmithKline
Hoffmann-La Roche
Merck
Pfizer
Tibotec-Virco
Vertex
ViroLogic

Source: see Financial Disclosures section (p 263) of Yeni PG, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251-265. (available for free download (no HTML viewing option) at http://www.iasusa.org/pub/index.html)

*********************************************************************************************************************************************
*****************************************************************************************************************************************

NOTE: While the concerns of commercial bias, corruption and kick-backs expressed here are serious and well-documented, they in no way endorse or support a thesis which denies any of the following:

(1) That HIV is necessary in the causation of the immune deficiency syndrome called AIDS;
(2) That HIV antibody tests accurately diagnose HIV in up to 98% of infected individuals after 4-12 weeks of infection;
(3) That antiretroviral medicines, while far from perfect, improve immune function and can extend life;
(4) That HIV is heterosexually as well as homosexually transmitted;
(5) That condoms, when used properly, can prevent HIV transmission;
(6) That HIV/AIDS is one of many serious public health challenges in many regions of Africa, Asia, and the Caribbean.

This site brought to you as an informational service and was definitively not made possible by a grant or gift--"educational," "unrestricted," or otherwise--by the likes of GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Abbott, Tibotec-Virco, Pfizer, Merck, Monogram, Triangle, Trimeris, Boehringer Ingelheim, Roche, Schering, Panacos, Pharmasset, Shire, Ortho Biotech, (Orchestra Therapeutics), (Tanox), Genentech, Takeda, Vertex, (Bayer Diagnostics), Siemens, Acambis, Achillion, Adventrx, Anadys, (AnorMed), Genzyme, Avexa, Depomed, Idenix, Koronis, Millenium, Progenics, (Therapy Edge), Advanced Biological Concepts, VirXSys, Human Genome Sciences or any of the rest.